PMA device
Elecsys Anti-HBc II
Roche Diagnostics Corp. · Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM, Class II) · First FDA decision Feb 9, 2018, newest May 8, 2023HIV, hepatitis and sexually transmitted infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
6
PMA pathway
Device trials
0
Naming "Elecsys Anti-HBc II"
MAUDE reports
69
Brand "Elecsys Anti-HBc II", since 2015
PubMed studies
2
Mentioning "Elecsys Anti-HBc II"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys Anti-HBc II
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 6 decisions filed under this name.
- Elecsys Anti-HBc IIPMA supplement
P100031-S028 · Decided May 8, 2023 · 195 days after receipt · Normal 180 Day Track
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Hepatitis Panel/Acute Hepatitis PanelNational determinationOn the books190.33Updated Oct 1, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisUnder reviewCAG-00436RUpdated Sep 23, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational analysisReview closedCAG-00436NUpdated Sep 22, 2026
- Screening for Hepatitis B Virus (HBV) InfectionNational analysisReview closedCAG-00447NUpdated Sep 22, 2026
- Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.5, Other nonspecific abnormal serum enzyme levels, as a covered indication)Coding analysisReview closedCAG-00335NUpdated Sep 14, 2026
- Hepatitis Panel/Acute Hepatitis Panel (Addition of ICD-9-CM 790.4, Elevation of Levels of Transaminase or Lactic Acid Dehydrogenase)Coding analysisReview closedCAG-00304NUpdated Sep 14, 2026
- Hepatitis Panel (Removal of ICD-9-CM Code 784.69, Other symbolic dysfunction, from the list of Codes Covered by Medicare)Coding analysisReview closedCAG-00283NUpdated Sep 14, 2026
- Screening for Hepatitis C Virus (HCV) in AdultsNational determinationOn the books210.13Updated Apr 7, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys Anti-HBc II", any status and sponsor, newest update first.
No registered device study names "Elecsys Anti-HBc II".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys Anti-HBc II", and for the whole product code for context.
This brand
69 reports: 69 malfunction, 0 injury, 0 death
Whole product code LOM
2,194 reports: 2,179 malfunction, 14 injury, 0 death
Newest reports for this brand
- Elecsys Anti-HBc IIMalfunction
1823260-2026-04333 · Received Oct 19, 2026 · Event dated Sep 22, 2026
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM)
Device problem as coded: False Negative Result
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Elecsys Anti-HBc II"[tiab]. The summary above synthesizes these.
- Multicenter Performance Evaluation of Elecsys Anti-HBc II, Anti-HCV II, HIV combi PT, HBsAg II, and Syphilis Immunoassays.
Hottenträger B, Hagedorn HJ, Bäcker E, et al. · Clin Lab · 2021Multicenter Study
- A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and Elecsys Anti-HBc in a Korean population.
Lee T, Yang JJ, Eom J, et al. · J Clin Virol · 2018Evaluation Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LOM.
- VITROS Immunodiagnostic Products Anti-HBc Reagent Pack and CalibratorOrtho-Clinical Diagnostics · PMA 2018
- Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgMRoche Diagnostics Corp. · PMA 2024
- Advia Centaur Hbc IGM Readypack ReagentsSiemens Healthcare Diagnostics · PMA 2016
- Immulite/Immulite 1000 & Immulite 2000 Anti-HbsSiemens Healthcare Diagnostics Products, Ltd. · PMA 2010
- Architect AusabAbbott Laboratories, Inc. · PMA 2024
- Elecsys HBsAg IIRoche Diagnostics, Inc. · PMA 2023
- Architect Core-MAbbott Laboratories · PMA 2020
- ADVIA Centaur HBsAgII (HBsII)Siemens Corp. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.